Arcus Biosciences
RCUS
187 hedge funds and large institutions have $948M invested in Arcus Biosciences in 2023 Q3 according to their latest regulatory filings, with 31 funds opening new positions, 53 increasing their positions, 73 reducing their positions, and 23 closing their positions.
43% more call options, than puts
Call options by funds: $22.6M | Put options by funds: $15.9M
35% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 23
3% more funds holding
Funds holding: 181 → 187 (+6)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
3.94% less ownership
Funds ownership: 74.82% → 70.89% (-3.9%)
15% less capital invested
Capital invested by funds: $1.11B → $948M (-$162M)
27% less repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 73
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$15.9M |
| 2 |
SCM
Suvretta Capital Management
New York
|
+$12M |
| 3 |
Barclays
London,
United Kingdom
|
+$6.12M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$5.97M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$4.47M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
-$28.2M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
-$15.2M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$14.2M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$9.04M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$5.03M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
201
Robeco Institutional Asset Management
Rotterdam,
Netherlands
| – | -$23.2K | -1,143 | Closed |
|
|
QT
202
Quantbot Technologies
New York
| – | -$6.09K | -300 | Closed |
|
|
CMBA
203
C.M. Bidwell & Associates
Honolulu,
Hawaii
| – | -$2.64K | -130 | Closed |
|
|
TAM
204
Tucker Asset Management
Littleton,
Colorado
| – | -$1.02K | -50 | Closed |
|
|
IPW
205
Impact Partnership Wealth
Marietta,
Georgia
| – | -$751 | -37 | Closed |
|
|
FCA
206
FinTrust Capital Advisors
Greenville,
South Carolina
| – | -$476 | -23 | Closed |
|
|
DI
207
Disciplined Investments
Tulsa,
Oklahoma
| – | -$81 | -4 | Closed |
|
|
C
208
Covestor
London,
United Kingdom
| – | -$20 | -1 | -17% |
|
|
SFG
209
Steward Financial Group
Colleyville,
Texas
| – | +$482 | +24 | New |
|
RCUS Hedge Fund Activity: Q3 2023 in Review
187 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Arcus Biosciences (RCUS) for Q3 2023, worth a combined $948M — down 15% from $1.11B a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new RCUS positions and 23 closed out — a net gain of 8 holders — while 53 added to existing stakes and 73 trimmed.
The largest buyer was Woodline Partners, adding an estimated $15.9M. The largest seller was Balyasny Asset Management, cutting an estimated $28.2M.
- 187 institutional investors held Arcus Biosciences (RCUS) as of Q3 2023, up from 181 in Q2 2023.
- Funds reported $948M of Arcus Biosciences stock for Q3 2023, down 15% quarter-over-quarter.
- 31 funds opened new Arcus Biosciences positions in Q3 2023 and 23 closed out, a net change of +8 holders.
- The largest Arcus Biosciences buyer in Q3 2023 was Woodline Partners, an estimated $15.9M added.
- The largest Arcus Biosciences seller in Q3 2023 was Balyasny Asset Management, an estimated $28.2M sold.
Based on aggregated 13F filings for Q3 2023.